Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors

BACKGROUND: Anti-angiogenic therapies such as bevacizumab upregulate hypoxia-inducible factor-1α (HIF-1α), a possible mechanism of drug resistance. Camptothecin analogues, including SN-38, have been shown to reduce the expression and transcriptional activity of HIF-1α in preclinical models. We hypot...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Invest New Drugs
Главные авторы: Jeong, Woondong, Ryun Park, Sook, Rapisarda, Annamaria, Fer, Nicole, Kinders, Robert J., Chen, Alice, Melillo, Giovanni, Turkbey, Baris, Steinberg, Seth M., Choyke, Peter, Doroshow, James H., Kummar, Shivaani
Формат: Artigo
Язык:Inglês
Опубликовано: 2013
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7670584/
https://ncbi.nlm.nih.gov/pubmed/24242862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0048-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы